These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2903509)

  • 21. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.
    Rapaport MH; Wolkowitz O; Kelsoe JR; Pato C; Konicki PE; Pickar D
    Neuropsychopharmacology; 1993 Sep; 9(2):111-5. PubMed ID: 8105790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
    Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M
    Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
    Yoshimura R; Ueda N; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):256-61. PubMed ID: 20218790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies of catecholamine metabolism in schizophrenia/psychosis--II.
    Maas JW; Contreras SA; Miller AL; Berman N; Bowden CL; Javors MA; Seleshi E; Weintraub SE
    Neuropsychopharmacology; 1993 Feb; 8(2):111-6. PubMed ID: 8471122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia.
    Hori H; Yoshimura R; Katsuki A; Atake K; Igata R; Konishi Y; Beppu H; Tominaga H
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
    Nikisch G; Baumann P; Kiessling B; Reinert M; Wiedemann G; Kehr J; Mathé AA; Piel M; Roesch F; Weisser H; Schneider P; Hertel A
    J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients.
    Hori H; Yoshimura R; Yamada Y; Ikenouchi A; Mitoma M; Ida Y; Nakamura J
    Int Clin Psychopharmacol; 2007 Jan; 22(1):21-7. PubMed ID: 17159456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of mianserin on negative symptoms in schizophrenia.
    Mizuki Y; Kajimura N; Imai T; Suetsugi M; Kai S; Kaneyuki H; Yamada M
    Int Clin Psychopharmacol; 1990 Apr; 5(2):83-95. PubMed ID: 1696292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the central dopaminergic index of plasma HVA in schizophrenia.
    Amin F; Davidson M; Kahn RS; Schmeidler J; Stern R; Knott PJ; Apter S
    Schizophr Bull; 1995; 21(1):53-66. PubMed ID: 7770741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reproducibility of plasma catecholamine metabolites in normal subjects.
    Amin F; Hashmi A; Stroe AE; Adebogun O; Densmore D; Knott PJ
    Biol Psychiatry; 1998 Feb; 43(3):233-5. PubMed ID: 9494706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal.
    Zander KJ; Fischer B; Zimmer R; Ackenheil M
    Psychopharmacology (Berl); 1981; 73(1):43-7. PubMed ID: 6112769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
    Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
    Psychiatry Res; 1992 Mar; 41(3):191-202. PubMed ID: 1594706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RBC and plasma choline in neuroleptic-treated schizophrenic patients.
    Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ
    Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF.
    Nikisch G; Baumann P; Wiedemann G; Kiessling B; Weisser H; Hertel A; Yoshitake T; Kehr J; Mathé AA
    J Clin Psychopharmacol; 2010 Oct; 30(5):496-503. PubMed ID: 20814316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Biol Psychiatry; 1992 Dec; 32(12):1102-7. PubMed ID: 1477190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma catecholamine metabolites and early response to haloperidol.
    Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
    J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma levels of metabolites of catecholamine in nicotine-dependent patients treated with varenicline.
    Umene-Nakano W; Yoshimura R; Yoshii C; Hayashi K; Ikenouchi-Sugita A; Katsuki A; Hori H; Nakamura J
    Nicotine Tob Res; 2012 Apr; 14(4):486-9. PubMed ID: 22006914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients.
    Zumárraga M; Dávila R; Basterreche N; Arrue A; Goienetxea B; Zamalloa MI; Erkoreka L; Bustamante S; Inchausti L; González-Torres MA; Guimón J
    Neurochem Int; 2010; 56(6-7):774-9. PubMed ID: 20206656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.